BRCA1; case report; colorectal (colon) cancer; exome sequencing (ES); homologous recombination deficiency (HRD); Oncology; Cancer Research
Abstract :
[en] Objective: The link between BRCA1 and homologous recombination deficiency (HRD) in cancer has gained importance with the emergence of new targeted cancer treatments, while the available data on the role of the gene in colorectal cancer (CRC) remain contradictory. The aim of this case series was to elucidate the role of known pathogenic BRCA1 variants in the development of early-onset CRC.
Design: Patients were evaluated using targeted next generation sequencing, exome sequencing and chromosomal microarray analysis of the paired germline and tumor samples. These results were used to calculate the HRD score and the frequency of mutational signatures in the tumors.
Results: Three patients with metastatic CRC were heterozygous for a previously known BRCA1 nonsense variant. All tumors showed remarkably high HRD scores, and the HRD-related signature 3 had the second highest contribution to the somatic pattern of variant accumulation in the samples (23% in 1 and 2, and 13% in sample 3).
Conclusions: A BRCA1 germline pathogenic variant can be involved in CRC development through HRD. Thus, BRCA1 testing should be considered in young patients with a personal history of microsatellite stable CRC as this could further allow a personalized treatment approach.
Disciplines :
Oncology
Author, co-author :
Freire, Maria Valeria ; Department of Human Genetics, GIGA Research Center - University of Liège and Centre Hospitalier Universitaire (CHU) Liège, Liège, Belgium
MARTIN, Marie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
Thissen, Romain ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique humaine
Van Marcke, Cédric; Institute for Experimental and Clinical Research (Institut de Recherche Expérimentale et Clinique (IREC), Pôle Molecular Imaging, Radiotherapy and Oncology (MIRO)), Université Catholique de Louvain (UCLouvain), Brussels, Belgium ; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium
SEGERS, Karin ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
SEPULCHRE, Edith ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
LEROI, Natacha ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
LETE, Céline ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
FASQUELLE, Corinne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
Radermacher, Jean; Department of Pathology, Institut de Pathologie et de Génétique, Charleroi, Belgium
Gokburun, Yeter; Department of Gastroenterology, Centre Hospitalier Régional Sambre et Meuse, Namur, Belgium
COLLIGNON, Joëlle ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Sacré, Anne ; Université de Liège - ULiège > Département des sciences de la vie > Phylogénomique des eucaryotes ; Onco-Hematology Department, Centre Hospitalier Régional (CHR) Verviers, Verviers, Belgium
JOSSE, Claire ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
PALMEIRA, Léonor ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
BOURS, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
This work was supported by a Télévie fellowship (MV.F., grant N° 7451419F), a grant from the CHU Liége (N° 981481200) and the WALGEMED grant (Région Wallonne, grant N° 1710180).
Wu W Koike A Takeshita T Ohta T. The Ubiquitin E3 Ligase Activity of BRCA1 and Its Biological Functions. Cell Div (2008) 3:1. doi: 10.1186/1747-1028-3-1
Miki Y Swensen J Shattuck-Eidens D Futreal PA Harshman K Tavtigian S et al. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene Brca1. Science (1994) 266(5182):66–71. doi: 10.1126/science.7545954
Mavaddat N Peock S Frost D Ellis S Platte R Fineberg E et al. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. J Natl Cancer Inst (2013) 105(11):812–22. doi: 10.1093/jnci/djt095
Schoen RE Weissfeld JL Kuller LH. Are Women With Breast, Endometrial, or Ovarian Cancer at Increased Risk for Colorectal Cancer? Am J Gastroenterol (1994) 89(6):835–42.
Mersch J Jackson M Park M Nebgen D Peterson SK Singletary C et al. Cancers Associated With BRCA1 and BRCA2 Mutations Other Than Breast and Ovarian. Cancer (2015) 121(2):269–75. doi: 10.1002/cncr.29041
Phelan CM Iqbal J Lynch HT Lubinski J Gronwald J Moller P et al. Incidence of Colorectal Cancer in BRCA1 and BRCA2 Mutation Carriers: Results From a Follow-Up Study. Br J Cancer (2014) 110(2):530–4. doi: 10.1038/bjc.2013.741
Cullinane CM Creavin B O’Connell EP Kelly L O’Sullivan MJ Corrigan MA et al. Risk of Colorectal Cancer Associated With BRCA1 and/or BRCA2 Mutation Carriers: Systematic Review and Meta-Analysis. BJS (British J Surgery) (2020) 107(8):951–9. doi: 10.1002/bjs.11603
Oh M McBride A Yun S Bhattacharjee S Slack M Martin JR et al. BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-Analysis. J Natl Cancer Inst (2018) 110(11):1178–89. doi: 10.1093/jnci/djy148
Lee Y-C Lee Y-L Li C-Y. BRCA Genes and Related Cancers: A Meta-Analysis From Epidemiological Cohort Studies. Medicina (2021) 57(9):905. doi: 10.3390/medicina57090905
Curtit E Benhamo V Gruel N Popova T Manie E Cottu P et al. First Description of a Sporadic Breast Cancer in a Woman With BRCA1 Germline Mutation. Oncotarget (2015) 6(34):35616–24. doi: 10.18632/oncotarget.5348
Song H Cicek MS Dicks E Harrington P Ramus SJ Cunningham JM et al. The Contribution of Deleterious Germline Mutations in BRCA1, BRCA2 and the Mismatch Repair Genes to Ovarian Cancer in the Population. Hum Mol Genet (2014) 23(17):4703–9. doi: 10.1093/hmg/ddu172
de Juan Jiménez I García Casado Z Palanca Suela S Esteban Cardeñosa E López Guerrero JA Segura Huerta Á et al. Novel and Recurrent BRCA1/BRCA2 Mutations in Early Onset and Familial Breast and Ovarian Cancer Detected in the Program of Genetic Counseling in Cancer of Valencian Community (Eastern Spain). Relationship of Family Phenotypes With Mutation Prevalence. Familial Cancer (2013) 12(4):767–77. doi: 10.1007/s10689-013-9622-2
Simard J Tonin P Durocher F Morgan K Rommens J Gingras S et al. Common Origins of BRCA1 Mutations in Canadian Breast and Ovarian Cancer Families. Nat Genet (1994) 8(4):392–8. doi: 10.1038/ng1294-392
Dørum A Heimdal K Hovig E Inganäs M Møller P. Penetrances of BRCA1 1675dela and 1135insa With Respect to Breast Cancer and Ovarian Cancer. Am J Hum Genet (1999) 65(3):671–9. doi: 10.1086/302530
Foretova L Machackova E Navratilova M Pavlu H Hruba M Lukesova M et al. BRCA1 and BRCA2 Mutations in Women With Familial or Early-Onset Breast/Ovarian Cancer in the Czech Republic. Hum Mutat (2004) 23(4):397–8. doi: 10.1002/humu.9226
Machackova E Foretova L Lukesova M Vasickova P Navratilova M Coene I et al. Spectrum and Characterisation of BRCA1 and BRCA2 Deleterious Mutations in High-Risk Czech Patients With Breast and/or Ovarian Cancer. BMC Cancer (2008) 8:140. doi: 10.1186/1471-2407-8-140
Laraqui A Uhrhammer N Lahlou-Amine I EL Rhaffouli H El Baghdadi J Dehayni M et al. Mutation Screening of the BRCA1 Gene in Early Onset and Familial Breast/Ovarian Cancer in Moroccan Population. Int J Med Sci (2012) 10(1):60–7. doi: 10.7150/ijms.5014
Janavičius R. Founder BRCA1/2 Mutations in the Europe: Implications for Hereditary Breast-Ovarian Cancer Prevention and Control. EPMA J (2010) 1(3):397–412. doi: 10.1007/s13167-010-0037-y
Behl S Hamel N de Ladurantaye M Lepage S Lapointe R Mes-Masson A-M et al. Founder BRCA1/BRCA2/PALB2 Pathogenic Variants in French-Canadian Breast Cancer Cases and Controls. Sci Rep (2020) 10:6491. doi: 10.1038/s41598-020-63100-w
Łukomska A Menkiszak J Gronwald J Tomiczek-Szwiec J Szwiec M Jasiówka M et al. Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients With Ovarian Cancer. Cancers (Basel) (2021) 13(4):849. doi: 10.3390/cancers13040849
Caputo S Benboudjema L Sinilnikova O Rouleau E Béroud C Lidereau R. Description and Analysis of Genetic Variants in French Hereditary Breast and Ovarian Cancer Families Recorded in the UMD-BRCA1/BRCA2 Databases. Nucleic Acids Res (2012) 40(Database issue):D992–1002. doi: 10.1093/nar/gkr1160
Favero F Joshi T Marquard AM Birkbak NJ Krzystanek M Li Q et al. Sequenza: Allele-Specific Copy Number and Mutation Profiles From Tumor Sequencing Data. Ann Oncol (2015) 26(1):64–70. doi: 10.1093/annonc/mdu479
Coleman RL Fleming GF Brady MF Swisher EM Steffensen KD Friedlander M et al. Veliparib With First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New Engl J Med (2019) 381:2403–15. doi: 10.1056/NEJMoa1909707
Blokzijl F Janssen R van Boxtel R Cuppen E. MutationalPatterns: Comprehensive Genome-Wide Analysis of Mutational Processes. Genome Med (2018) 10(1):33. doi: 10.1186/s13073-018-0539-0
Alexandrov LB Nik-Zainal S Wedge DC Aparicio SAJR Behjati S Biankin AV et al. Signatures of Mutational Processes in Human Cancer. Nature (2013) 500(7463):415–21. doi: 10.1038/nature12477
Sopik V Phelan C Cybulski C Narod SA. BRCA1 and BRCA2 Mutations and the Risk for Colorectal Cancer. Clin Genet (2015) 87(5):411–8. doi: 10.1111/cge.12497
Grinshpun A Halpern N Granit RZ Hubert A Hamburger T Laitman Y et al. Phenotypic Characteristics of Colorectal Cancer in BRCA1/2 Mutation Carriers. Eur J Hum Genet (2018) 26(3):382–6. doi: 10.1038/s41431-017-0067-1
Soyano AE Baldeo C Kasi PM. BRCA Mutation and Its Association With Colorectal Cancer. Clin Colorectal Cancer (2018) 17(4):e647–50. doi: 10.1016/j.clcc.2018.06.006
Maxwell KN Domchek SM Nathanson KL Robson ME. Population Frequency of Germline BRCA1/2 Mutations. JCO (2016) 34(34):4183–5. doi: 10.1200/JCO.2016.67.0554
Evans DG Clancy T Hill J Tischkowitz M. Is There Really an Increased Risk of Early Colorectal Cancer in Women With BRCA1 Pathogenic Mutations? Clin Genet (2016) 89(3):399–9. doi: 10.1111/cge.12687
Silvestri V Leslie G Barnes DR CIMBA GroupAgnarsson BA Aittomäki K et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol (2020) 6(8):1218–30. doi: 10.1001/jamaoncol.2020.2134
Du C Peng Y He Y Chen G Chen H. Low Levels of BRCA1 Protein Expression Predict a Worse Prognosis in Stage I–II Colon Cancer. Int J Biol Markers (2021) 36(1):47–53. doi: 10.1177/1724600820986572
Alexandrov LB Kim J Haradhvala NJ Huang MN Tian Ng AW Wu Y et al. The Repertoire of Mutational Signatures in Human Cancer. Nature (2020) 578(7793):94–101. doi: 10.1038/s41586-020-1943-3
Abkevich V Timms KM Hennessy BT Potter J Carey MS Meyer LA et al. Patterns of Genomic Loss of Heterozygosity Predict Homologous Recombination Repair Defects in Epithelial Ovarian Cancer. Br J Cancer (2012) 107(10):1776–82. doi: 10.1038/bjc.2012.451
Birkbak NJ Wang ZC Kim J-Y Eklund AC Li Q Tian R et al. Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA Damaging Agents. Cancer Discov (2012) 2(4):366–75. doi: 10.1158/2159-8290.CD-11-0206
Popova T Manié E Rieunier G Caux-Moncoutier V Tirapo C Dubois T et al. Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-Like Breast Carcinomas With BRCA1/2 Inactivation. Cancer Res (2012) 72(21):5454–62. doi: 10.1158/0008-5472.CAN-12-1470
Rose M Burgess JT O’Byrne K Richard DJ Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol (2020) 8:879. doi: 10.3389/fcell.2020.564601
